Novo Nordisk’s experimental weight-loss drug, monlunabant, showed promising results in a Phase 2 trial, but investors reacted negatively due to safety concerns and limited efficacy at higher doses. This news sent shares of Corbus Pharmaceuticals, a competitor developing a similar drug, plummeting by nearly 60%.